Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.
Microbiology Unit, Interdisciplinary Biosciences, Belgian Nuclear Research Centre, SCK-CEN, Mol, Belgium.
Nat Commun. 2021 Apr 14;12(1):2241. doi: 10.1038/s41467-021-22302-0.
Antibiotic-induced modulation of the intestinal microbiota can lead to Clostridioides difficile infection (CDI), which is associated with considerable morbidity, mortality, and healthcare-costs globally. Therefore, identification of markers predictive of CDI could substantially contribute to guiding therapy and decreasing the infection burden. Here, we analyze the intestinal microbiota of hospitalized patients at increased CDI risk in a prospective, 90-day cohort-study before and after antibiotic treatment and at diarrhea onset. We show that patients developing CDI already exhibit significantly lower diversity before antibiotic treatment and a distinct microbiota enriched in Enterococcus and depleted of Ruminococcus, Blautia, Prevotella and Bifidobacterium compared to non-CDI patients. We find that antibiotic treatment-induced dysbiosis is class-specific with beta-lactams further increasing enterococcal abundance. Our findings, validated in an independent prospective patient cohort developing CDI, can be exploited to enrich for high-risk patients in prospective clinical trials, and to develop predictive microbiota-based diagnostics for management of patients at risk for CDI.
抗生素诱导的肠道微生物群失调可导致艰难梭菌感染(CDI),这在全球范围内与相当高的发病率、死亡率和医疗成本有关。因此,确定预测 CDI 的标志物将大大有助于指导治疗并降低感染负担。在这里,我们分析了在抗生素治疗前后和腹泻发作前处于 CDI 高风险的住院患者的肠道微生物群,这是一项前瞻性的 90 天队列研究。我们发现,与非 CDI 患者相比,发生 CDI 的患者在抗生素治疗前的多样性明显较低,且微生物群中肠球菌富集,而瘤胃球菌、布劳特氏菌、普雷沃氏菌和双歧杆菌减少。我们发现,抗生素治疗诱导的菌群失调具有特异性,β-内酰胺类抗生素进一步增加了肠球菌的丰度。我们的发现,在发生 CDI 的独立前瞻性患者队列中得到了验证,可用于富集前瞻性临床试验中的高危患者,并开发基于预测性微生物组的诊断方法,以管理 CDI 风险患者。